Psoriasis Clinical Trials Near You

The psoriasis treatment landscape continues to evolve beyond injectable biologics. While IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab) and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) remain highly effective, clinical trials are focused on oral small molecules that could offer similar skin clearance without injections.

TYK2 inhibitors represent the most significant emerging drug class. Deucravacitinib (Sotyktu) was the first FDA-approved TYK2 inhibitor for psoriasis, and next-generation TYK2 compounds are in Phase 2–3 trials aiming for improved PASI 90 and PASI 100 clearance rates. Unlike older JAK inhibitors (which carried cardiovascular and malignancy boxed warnings), TYK2 inhibitors selectively target a narrower signaling pathway, potentially offering a better long-term safety profile for chronic disease.

Treat-to-target approaches are gaining traction in trials, where treatment is escalated or switched based on achieving specific PASI targets within defined timeframes — similar to strategies already standard in diabetes and rheumatoid arthritis management.

For patients with psoriatic arthritis (PsA) co-occurring with skin psoriasis, several trials test dual-domain efficacy — medications that clear both skin plaques and joint inflammation simultaneously. IL-17A/F dual inhibitors like bimekizumab have shown particular promise in these combined disease states.

Patient considerations: Psoriasis trials measure skin clearance using PASI scores at 12–16 weeks, with photography of affected areas at each visit. Many trials accept patients who have failed one or more biologic therapies, so prior treatment experience often qualifies rather than disqualifies you. Expect regular dermatology visits every 2–4 weeks during the active treatment period.